Advertisement

Index by author

March 01, 1994; Volume 22,Issue 2

A

  1. Agostini, O

    1. Metabolism of isbufylline in humans. Isolation, identification, and synthesis of plasma and urine metabolites.
      O Agostini, G Bonacchi, G Coppini, E Toja, A Triolo, S Manzini, G Pieraccini and G Moneti
      Drug Metabolism and Disposition March 1994, 22 (2) 259-268;

  2. Arison, B H

    1. Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2 (1H)-one (L-696,229), an HIV-1 reverse transcriptase inhibitor, by rat liver slices and in humans.
      S K Balani, L R Kauffman, B H Arison, T V Olah, M E Goldman, S L Varga, J A O'Brien, H G Ramjit, C S Rooney and J M Hoffman
      Drug Metabolism and Disposition March 1994, 22 (2) 200-205;

B

  1. Balani, S K

    1. Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2 (1H)-one (L-696,229), an HIV-1 reverse transcriptase inhibitor, by rat liver slices and in humans.
      S K Balani, L R Kauffman, B H Arison, T V Olah, M E Goldman, S L Varga, J A O'Brien, H G Ramjit, C S Rooney and J M Hoffman
      Drug Metabolism and Disposition March 1994, 22 (2) 200-205;
    2. In vitro metabolism of L-696,229, an HIV-1 reverse transcriptase inhibitor in rats and humans. Hepatic and extrahepatic metabolism and identification of enzymes involved in the hepatic metabolism.
      T Prueksaritanont, L M Dwyer, S K Balani and A D Theoharides
      Drug Metabolism and Disposition March 1994, 22 (2) 281-288;

  2. Baldeck, J P

    1. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron.
      V Fischer, A E Vickers, F Heitz, S Mahadevan, J P Baldeck, P Minery and R Tynes
      Drug Metabolism and Disposition March 1994, 22 (2) 269-274;

  3. Bekersky, I

    1. The pharmacokinetics of 1,3-di(4-imidazolino-2-methoxyphenoxy) propane.lactate (DMP.lactate), a new agent against opportunistic infections, in male beagle dogs.
      I Bekersky, R J Puhl, G Hanson and S Mong
      Drug Metabolism and Disposition March 1994, 22 (2) 233-236;

  4. Bonacchi, G

    1. Metabolism of isbufylline in humans. Isolation, identification, and synthesis of plasma and urine metabolites.
      O Agostini, G Bonacchi, G Coppini, E Toja, A Triolo, S Manzini, G Pieraccini and G Moneti
      Drug Metabolism and Disposition March 1994, 22 (2) 259-268;

  5. Bork, V

    1. Milacemide metabolism in rat liver and brain slices by solids NMR.
      J R Garbow, W P Ridley, V Bork, Y Pan and J Schaefer
      Drug Metabolism and Disposition March 1994, 22 (2) 298-303;

  6. Brouwer, K L

    1. Bile flow but not enterohepatic recirculation influences the pharmacokinetics of ranitidine in the rat.
      A B Suttle and K L Brouwer
      Drug Metabolism and Disposition March 1994, 22 (2) 224-232;

  7. Bruelisauer, A

    1. Absorption and disposition of SDZ IMM 125, a new cyclosporine derivative, in rats after single and repeated administration.
      A Bruelisauer, R Kawai, P Misslin and M Lemaire
      Drug Metabolism and Disposition March 1994, 22 (2) 194-199;

C

  1. Chen, Q

    1. Salicylate inhibits the renal transport of inorganic sulfate in rat membrane vesicle preparations.
      I M Darling, M L Mammarella, Q Chen and M E Morris
      Drug Metabolism and Disposition March 1994, 22 (2) 318-323;

  2. Chenery, R J

    1. Use of rat and human in vitro systems to assess the effectiveness and enzymology of deoxyguanine analogs as prodrugs of an antiviral agent.
      A W Harrell, S M Wheeler, P East, S E Clarke and R J Chenery
      Drug Metabolism and Disposition March 1994, 22 (2) 189-193;

  3. Cheng, X

    1. Solvolytic formation of 1,2-dichloro-3,4-epoxybutane from butadiene monoxide under physiological conditions.
      X Cheng, C Maniglier-Poulet, D Ross and J A Ruth
      Drug Metabolism and Disposition March 1994, 22 (2) 206-210;

  4. Clarke, S E

    1. Use of rat and human in vitro systems to assess the effectiveness and enzymology of deoxyguanine analogs as prodrugs of an antiviral agent.
      A W Harrell, S M Wheeler, P East, S E Clarke and R J Chenery
      Drug Metabolism and Disposition March 1994, 22 (2) 189-193;

  5. Cole, C A

    1. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma.
      R F Mayol, C A Cole, G M Luke, K L Colson and E H Kerns
      Drug Metabolism and Disposition March 1994, 22 (2) 304-311;

  6. Colletti, A E

    1. Disposition of the angiotensin II receptor antagonist L-158,809 in rats and rhesus monkeys.
      A E Colletti and P A Krieter
      Drug Metabolism and Disposition March 1994, 22 (2) 183-188;

  7. Collins, J M

    1. Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.
      R W Klecker, C A Jamis-Dow, M J Egorin, K Erkmen, R J Parker, R Stevens and J M Collins
      Drug Metabolism and Disposition March 1994, 22 (2) 254-258;

  8. Colson, K L

    1. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma.
      R F Mayol, C A Cole, G M Luke, K L Colson and E H Kerns
      Drug Metabolism and Disposition March 1994, 22 (2) 304-311;

  9. Coppini, G

    1. Metabolism of isbufylline in humans. Isolation, identification, and synthesis of plasma and urine metabolites.
      O Agostini, G Bonacchi, G Coppini, E Toja, A Triolo, S Manzini, G Pieraccini and G Moneti
      Drug Metabolism and Disposition March 1994, 22 (2) 259-268;

D

  1. Dalgaard, L

    1. Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid.
      L Dalgaard, R K Hjortkjaer, B Regnier and L Nordholm
      Drug Metabolism and Disposition March 1994, 22 (2) 289-293;

  2. Darling, I M

    1. Salicylate inhibits the renal transport of inorganic sulfate in rat membrane vesicle preparations.
      I M Darling, M L Mammarella, Q Chen and M E Morris
      Drug Metabolism and Disposition March 1994, 22 (2) 318-323;

  3. Dwyer, L M

    1. In vitro metabolism of L-696,229, an HIV-1 reverse transcriptase inhibitor in rats and humans. Hepatic and extrahepatic metabolism and identification of enzymes involved in the hepatic metabolism.
      T Prueksaritanont, L M Dwyer, S K Balani and A D Theoharides
      Drug Metabolism and Disposition March 1994, 22 (2) 281-288;

E

  1. East, P

    1. Use of rat and human in vitro systems to assess the effectiveness and enzymology of deoxyguanine analogs as prodrugs of an antiviral agent.
      A W Harrell, S M Wheeler, P East, S E Clarke and R J Chenery
      Drug Metabolism and Disposition March 1994, 22 (2) 189-193;

  2. Egorin, M J

    1. Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.
      R W Klecker, C A Jamis-Dow, M J Egorin, K Erkmen, R J Parker, R Stevens and J M Collins
      Drug Metabolism and Disposition March 1994, 22 (2) 254-258;

  3. Erkmen, K

    1. Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.
      R W Klecker, C A Jamis-Dow, M J Egorin, K Erkmen, R J Parker, R Stevens and J M Collins
      Drug Metabolism and Disposition March 1994, 22 (2) 254-258;

F

  1. Faiman, M D

    1. NADPH-dependent, regioselective S-oxidation of a thionosulfur- and thioether-containing xenobiotic, diethyldithiocarbamate methyl ester by rat liver microsomes.
      A Madan and M D Faiman
      Drug Metabolism and Disposition March 1994, 22 (2) 324-330;

  2. Fischer, V

    1. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron.
      V Fischer, A E Vickers, F Heitz, S Mahadevan, J P Baldeck, P Minery and R Tynes
      Drug Metabolism and Disposition March 1994, 22 (2) 269-274;

  3. Forkert, P G

    1. Induction and regulation of CYP2E1 in murine liver after acute and chronic acetone administration.
      P G Forkert, Z M Redza, S Mangos, S S Park and S P Tam
      Drug Metabolism and Disposition March 1994, 22 (2) 248-253;

G

  1. Garbow, J R

    1. Milacemide metabolism in rat liver and brain slices by solids NMR.
      J R Garbow, W P Ridley, V Bork, Y Pan and J Schaefer
      Drug Metabolism and Disposition March 1994, 22 (2) 298-303;

  2. Garland, W A

    1. Disposition of [14C]acitretin in humans following oral administration.
      F Rubio, B K Jensen, L Henderson, W A Garland, A Szuna and C Town
      Drug Metabolism and Disposition March 1994, 22 (2) 211-215;

  3. Goldman, M E

    1. Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2 (1H)-one (L-696,229), an HIV-1 reverse transcriptase inhibitor, by rat liver slices and in humans.
      S K Balani, L R Kauffman, B H Arison, T V Olah, M E Goldman, S L Varga, J A O'Brien, H G Ramjit, C S Rooney and J M Hoffman
      Drug Metabolism and Disposition March 1994, 22 (2) 200-205;

H

  1. Hanson, G

    1. The pharmacokinetics of 1,3-di(4-imidazolino-2-methoxyphenoxy) propane.lactate (DMP.lactate), a new agent against opportunistic infections, in male beagle dogs.
      I Bekersky, R J Puhl, G Hanson and S Mong
      Drug Metabolism and Disposition March 1994, 22 (2) 233-236;

  2. Harrell, A W

    1. Use of rat and human in vitro systems to assess the effectiveness and enzymology of deoxyguanine analogs as prodrugs of an antiviral agent.
      A W Harrell, S M Wheeler, P East, S E Clarke and R J Chenery
      Drug Metabolism and Disposition March 1994, 22 (2) 189-193;

  3. Heitz, F

    1. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron.
      V Fischer, A E Vickers, F Heitz, S Mahadevan, J P Baldeck, P Minery and R Tynes
      Drug Metabolism and Disposition March 1994, 22 (2) 269-274;

  4. Henderson, L

    1. Disposition of [14C]acitretin in humans following oral administration.
      F Rubio, B K Jensen, L Henderson, W A Garland, A Szuna and C Town
      Drug Metabolism and Disposition March 1994, 22 (2) 211-215;

  5. Hjortkjaer, R K

    1. Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid.
      L Dalgaard, R K Hjortkjaer, B Regnier and L Nordholm
      Drug Metabolism and Disposition March 1994, 22 (2) 289-293;

  6. Hoffman, J M

    1. Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2 (1H)-one (L-696,229), an HIV-1 reverse transcriptase inhibitor, by rat liver slices and in humans.
      S K Balani, L R Kauffman, B H Arison, T V Olah, M E Goldman, S L Varga, J A O'Brien, H G Ramjit, C S Rooney and J M Hoffman
      Drug Metabolism and Disposition March 1994, 22 (2) 200-205;

  7. Horecký, J

    1. NG-nitro-L-arginine is not involved in enterohepatic cycling in rats.
      V K Piotrovskij, Z Kállay, J Horecký, T Trnovec, G Raberger and K Krejcy
      Drug Metabolism and Disposition March 1994, 22 (2) 338-339;

I

  1. Iba, K

    1. Pharmacokinetics of SM-10888 and its metabolites depending on their physicochemical properties.
      M Yabuki, T Mine, K Iba, I Nakatsuka and A Yoshitake
      Drug Metabolism and Disposition March 1994, 22 (2) 294-297;

J

  1. Jamis-Dow, C A

    1. Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.
      R W Klecker, C A Jamis-Dow, M J Egorin, K Erkmen, R J Parker, R Stevens and J M Collins
      Drug Metabolism and Disposition March 1994, 22 (2) 254-258;

  2. Jensen, B K

    1. Disposition of [14C]acitretin in humans following oral administration.
      F Rubio, B K Jensen, L Henderson, W A Garland, A Szuna and C Town
      Drug Metabolism and Disposition March 1994, 22 (2) 211-215;

  3. Juchau, M R

    1. Cytochrome P-450-dependent biotransformation of 2-acetylaminofluorene in cell-free preparations of human embryonic hepatic, adrenal, renal, pulmonary, and cardiac tissues.
      M J Namkung, H L Yang and M R Juchau
      Drug Metabolism and Disposition March 1994, 22 (2) 331-337;

K

  1. Kállay, Z

    1. NG-nitro-L-arginine is not involved in enterohepatic cycling in rats.
      V K Piotrovskij, Z Kállay, J Horecký, T Trnovec, G Raberger and K Krejcy
      Drug Metabolism and Disposition March 1994, 22 (2) 338-339;

  2. Kauffman, L R

    1. Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2 (1H)-one (L-696,229), an HIV-1 reverse transcriptase inhibitor, by rat liver slices and in humans.
      S K Balani, L R Kauffman, B H Arison, T V Olah, M E Goldman, S L Varga, J A O'Brien, H G Ramjit, C S Rooney and J M Hoffman
      Drug Metabolism and Disposition March 1994, 22 (2) 200-205;

  3. Kawai, R

    1. Absorption and disposition of SDZ IMM 125, a new cyclosporine derivative, in rats after single and repeated administration.
      A Bruelisauer, R Kawai, P Misslin and M Lemaire
      Drug Metabolism and Disposition March 1994, 22 (2) 194-199;

  4. Kerns, E H

    1. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma.
      R F Mayol, C A Cole, G M Luke, K L Colson and E H Kerns
      Drug Metabolism and Disposition March 1994, 22 (2) 304-311;

  5. Khetarpal, V K

    1. Dispositional characteristics of a tyrosine kinase inhibitor (RG 14620) in rats and rabbits following intravenous administration or dermal application.
      V K Khetarpal, P M Markham and J A Ziemniak
      Drug Metabolism and Disposition March 1994, 22 (2) 216-223;

  6. Khokhar, A R

    1. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
      Y Kido, A R Khokhar, M Yoshida, G W Thai and Z H Siddik
      Drug Metabolism and Disposition March 1994, 22 (2) 312-317;

  7. Kido, Y

    1. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
      Y Kido, A R Khokhar, M Yoshida, G W Thai and Z H Siddik
      Drug Metabolism and Disposition March 1994, 22 (2) 312-317;

  8. Klecker, R W

    1. Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.
      R W Klecker, C A Jamis-Dow, M J Egorin, K Erkmen, R J Parker, R Stevens and J M Collins
      Drug Metabolism and Disposition March 1994, 22 (2) 254-258;

  9. Krejcy, K

    1. NG-nitro-L-arginine is not involved in enterohepatic cycling in rats.
      V K Piotrovskij, Z Kállay, J Horecký, T Trnovec, G Raberger and K Krejcy
      Drug Metabolism and Disposition March 1994, 22 (2) 338-339;

  10. Krieter, P A

    1. Disposition of the angiotensin II receptor antagonist L-158,809 in rats and rhesus monkeys.
      A E Colletti and P A Krieter
      Drug Metabolism and Disposition March 1994, 22 (2) 183-188;

L

  1. Lemaire, M

    1. Absorption and disposition of SDZ IMM 125, a new cyclosporine derivative, in rats after single and repeated administration.
      A Bruelisauer, R Kawai, P Misslin and M Lemaire
      Drug Metabolism and Disposition March 1994, 22 (2) 194-199;

  2. Luke, G M

    1. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma.
      R F Mayol, C A Cole, G M Luke, K L Colson and E H Kerns
      Drug Metabolism and Disposition March 1994, 22 (2) 304-311;

M

  1. Madan, A

    1. NADPH-dependent, regioselective S-oxidation of a thionosulfur- and thioether-containing xenobiotic, diethyldithiocarbamate methyl ester by rat liver microsomes.
      A Madan and M D Faiman
      Drug Metabolism and Disposition March 1994, 22 (2) 324-330;

  2. Mahadevan, S

    1. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron.
      V Fischer, A E Vickers, F Heitz, S Mahadevan, J P Baldeck, P Minery and R Tynes
      Drug Metabolism and Disposition March 1994, 22 (2) 269-274;

  3. Mammarella, M L

    1. Salicylate inhibits the renal transport of inorganic sulfate in rat membrane vesicle preparations.
      I M Darling, M L Mammarella, Q Chen and M E Morris
      Drug Metabolism and Disposition March 1994, 22 (2) 318-323;

  4. Mangos, S

    1. Induction and regulation of CYP2E1 in murine liver after acute and chronic acetone administration.
      P G Forkert, Z M Redza, S Mangos, S S Park and S P Tam
      Drug Metabolism and Disposition March 1994, 22 (2) 248-253;

  5. Maniglier-Poulet, C

    1. Solvolytic formation of 1,2-dichloro-3,4-epoxybutane from butadiene monoxide under physiological conditions.
      X Cheng, C Maniglier-Poulet, D Ross and J A Ruth
      Drug Metabolism and Disposition March 1994, 22 (2) 206-210;

  6. Manzini, S

    1. Metabolism of isbufylline in humans. Isolation, identification, and synthesis of plasma and urine metabolites.
      O Agostini, G Bonacchi, G Coppini, E Toja, A Triolo, S Manzini, G Pieraccini and G Moneti
      Drug Metabolism and Disposition March 1994, 22 (2) 259-268;

  7. Marathe, P H

    1. Metabolic kinetics of pseudoracemic propranolol in human liver microsomes. Enantioselectivity and quinidine inhibition.
      P H Marathe, D D Shen and W L Nelson
      Drug Metabolism and Disposition March 1994, 22 (2) 237-247;

  8. Markham, P M

    1. Dispositional characteristics of a tyrosine kinase inhibitor (RG 14620) in rats and rabbits following intravenous administration or dermal application.
      V K Khetarpal, P M Markham and J A Ziemniak
      Drug Metabolism and Disposition March 1994, 22 (2) 216-223;

  9. Mayol, R F

    1. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma.
      R F Mayol, C A Cole, G M Luke, K L Colson and E H Kerns
      Drug Metabolism and Disposition March 1994, 22 (2) 304-311;

  10. Mine, T

    1. Pharmacokinetics of SM-10888 and its metabolites depending on their physicochemical properties.
      M Yabuki, T Mine, K Iba, I Nakatsuka and A Yoshitake
      Drug Metabolism and Disposition March 1994, 22 (2) 294-297;

  11. Minery, P

    1. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron.
      V Fischer, A E Vickers, F Heitz, S Mahadevan, J P Baldeck, P Minery and R Tynes
      Drug Metabolism and Disposition March 1994, 22 (2) 269-274;

  12. Misslin, P

    1. Absorption and disposition of SDZ IMM 125, a new cyclosporine derivative, in rats after single and repeated administration.
      A Bruelisauer, R Kawai, P Misslin and M Lemaire
      Drug Metabolism and Disposition March 1994, 22 (2) 194-199;

  13. Moneti, G

    1. Metabolism of isbufylline in humans. Isolation, identification, and synthesis of plasma and urine metabolites.
      O Agostini, G Bonacchi, G Coppini, E Toja, A Triolo, S Manzini, G Pieraccini and G Moneti
      Drug Metabolism and Disposition March 1994, 22 (2) 259-268;

  14. Mong, S

    1. The pharmacokinetics of 1,3-di(4-imidazolino-2-methoxyphenoxy) propane.lactate (DMP.lactate), a new agent against opportunistic infections, in male beagle dogs.
      I Bekersky, R J Puhl, G Hanson and S Mong
      Drug Metabolism and Disposition March 1994, 22 (2) 233-236;

  15. Morris, M E

    1. Salicylate inhibits the renal transport of inorganic sulfate in rat membrane vesicle preparations.
      I M Darling, M L Mammarella, Q Chen and M E Morris
      Drug Metabolism and Disposition March 1994, 22 (2) 318-323;

N

  1. Nakatsuka, I

    1. Pharmacokinetics of SM-10888 and its metabolites depending on their physicochemical properties.
      M Yabuki, T Mine, K Iba, I Nakatsuka and A Yoshitake
      Drug Metabolism and Disposition March 1994, 22 (2) 294-297;

  2. Namkung, M J

    1. Cytochrome P-450-dependent biotransformation of 2-acetylaminofluorene in cell-free preparations of human embryonic hepatic, adrenal, renal, pulmonary, and cardiac tissues.
      M J Namkung, H L Yang and M R Juchau
      Drug Metabolism and Disposition March 1994, 22 (2) 331-337;

  3. Nelson, W L

    1. Metabolic kinetics of pseudoracemic propranolol in human liver microsomes. Enantioselectivity and quinidine inhibition.
      P H Marathe, D D Shen and W L Nelson
      Drug Metabolism and Disposition March 1994, 22 (2) 237-247;

  4. Nordholm, L

    1. Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid.
      L Dalgaard, R K Hjortkjaer, B Regnier and L Nordholm
      Drug Metabolism and Disposition March 1994, 22 (2) 289-293;

O

  1. O'Brien, J A

    1. Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2 (1H)-one (L-696,229), an HIV-1 reverse transcriptase inhibitor, by rat liver slices and in humans.
      S K Balani, L R Kauffman, B H Arison, T V Olah, M E Goldman, S L Varga, J A O'Brien, H G Ramjit, C S Rooney and J M Hoffman
      Drug Metabolism and Disposition March 1994, 22 (2) 200-205;

  2. Olah, T V

    1. Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2 (1H)-one (L-696,229), an HIV-1 reverse transcriptase inhibitor, by rat liver slices and in humans.
      S K Balani, L R Kauffman, B H Arison, T V Olah, M E Goldman, S L Varga, J A O'Brien, H G Ramjit, C S Rooney and J M Hoffman
      Drug Metabolism and Disposition March 1994, 22 (2) 200-205;

P

  1. Pan, Y

    1. Milacemide metabolism in rat liver and brain slices by solids NMR.
      J R Garbow, W P Ridley, V Bork, Y Pan and J Schaefer
      Drug Metabolism and Disposition March 1994, 22 (2) 298-303;

  2. Park, S S

    1. Induction and regulation of CYP2E1 in murine liver after acute and chronic acetone administration.
      P G Forkert, Z M Redza, S Mangos, S S Park and S P Tam
      Drug Metabolism and Disposition March 1994, 22 (2) 248-253;

  3. Parker, R J

    1. Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.
      R W Klecker, C A Jamis-Dow, M J Egorin, K Erkmen, R J Parker, R Stevens and J M Collins
      Drug Metabolism and Disposition March 1994, 22 (2) 254-258;

  4. Pieraccini, G

    1. Metabolism of isbufylline in humans. Isolation, identification, and synthesis of plasma and urine metabolites.
      O Agostini, G Bonacchi, G Coppini, E Toja, A Triolo, S Manzini, G Pieraccini and G Moneti
      Drug Metabolism and Disposition March 1994, 22 (2) 259-268;

  5. Piotrovskij, V K

    1. NG-nitro-L-arginine is not involved in enterohepatic cycling in rats.
      V K Piotrovskij, Z Kállay, J Horecký, T Trnovec, G Raberger and K Krejcy
      Drug Metabolism and Disposition March 1994, 22 (2) 338-339;

  6. Prueksaritanont, T

    1. In vitro metabolism of L-696,229, an HIV-1 reverse transcriptase inhibitor in rats and humans. Hepatic and extrahepatic metabolism and identification of enzymes involved in the hepatic metabolism.
      T Prueksaritanont, L M Dwyer, S K Balani and A D Theoharides
      Drug Metabolism and Disposition March 1994, 22 (2) 281-288;

  7. Puhl, R J

    1. The pharmacokinetics of 1,3-di(4-imidazolino-2-methoxyphenoxy) propane.lactate (DMP.lactate), a new agent against opportunistic infections, in male beagle dogs.
      I Bekersky, R J Puhl, G Hanson and S Mong
      Drug Metabolism and Disposition March 1994, 22 (2) 233-236;

R

  1. Raberger, G

    1. NG-nitro-L-arginine is not involved in enterohepatic cycling in rats.
      V K Piotrovskij, Z Kállay, J Horecký, T Trnovec, G Raberger and K Krejcy
      Drug Metabolism and Disposition March 1994, 22 (2) 338-339;

  2. Ramjit, H G

    1. Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2 (1H)-one (L-696,229), an HIV-1 reverse transcriptase inhibitor, by rat liver slices and in humans.
      S K Balani, L R Kauffman, B H Arison, T V Olah, M E Goldman, S L Varga, J A O'Brien, H G Ramjit, C S Rooney and J M Hoffman
      Drug Metabolism and Disposition March 1994, 22 (2) 200-205;

  3. Redza, Z M

    1. Induction and regulation of CYP2E1 in murine liver after acute and chronic acetone administration.
      P G Forkert, Z M Redza, S Mangos, S S Park and S P Tam
      Drug Metabolism and Disposition March 1994, 22 (2) 248-253;

  4. Regnier, B

    1. Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid.
      L Dalgaard, R K Hjortkjaer, B Regnier and L Nordholm
      Drug Metabolism and Disposition March 1994, 22 (2) 289-293;

  5. Ridley, W P

    1. Milacemide metabolism in rat liver and brain slices by solids NMR.
      J R Garbow, W P Ridley, V Bork, Y Pan and J Schaefer
      Drug Metabolism and Disposition March 1994, 22 (2) 298-303;

  6. Rooney, C S

    1. Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2 (1H)-one (L-696,229), an HIV-1 reverse transcriptase inhibitor, by rat liver slices and in humans.
      S K Balani, L R Kauffman, B H Arison, T V Olah, M E Goldman, S L Varga, J A O'Brien, H G Ramjit, C S Rooney and J M Hoffman
      Drug Metabolism and Disposition March 1994, 22 (2) 200-205;

  7. Ross, D

    1. Solvolytic formation of 1,2-dichloro-3,4-epoxybutane from butadiene monoxide under physiological conditions.
      X Cheng, C Maniglier-Poulet, D Ross and J A Ruth
      Drug Metabolism and Disposition March 1994, 22 (2) 206-210;

  8. Rubio, F

    1. Disposition of [14C]acitretin in humans following oral administration.
      F Rubio, B K Jensen, L Henderson, W A Garland, A Szuna and C Town
      Drug Metabolism and Disposition March 1994, 22 (2) 211-215;

  9. Ruth, J A

    1. Solvolytic formation of 1,2-dichloro-3,4-epoxybutane from butadiene monoxide under physiological conditions.
      X Cheng, C Maniglier-Poulet, D Ross and J A Ruth
      Drug Metabolism and Disposition March 1994, 22 (2) 206-210;

S

  1. Schaefer, J

    1. Milacemide metabolism in rat liver and brain slices by solids NMR.
      J R Garbow, W P Ridley, V Bork, Y Pan and J Schaefer
      Drug Metabolism and Disposition March 1994, 22 (2) 298-303;

  2. Shen, D D

    1. Metabolic kinetics of pseudoracemic propranolol in human liver microsomes. Enantioselectivity and quinidine inhibition.
      P H Marathe, D D Shen and W L Nelson
      Drug Metabolism and Disposition March 1994, 22 (2) 237-247;

  3. Siddik, Z H

    1. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
      Y Kido, A R Khokhar, M Yoshida, G W Thai and Z H Siddik
      Drug Metabolism and Disposition March 1994, 22 (2) 312-317;

  4. Stevens, R

    1. Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.
      R W Klecker, C A Jamis-Dow, M J Egorin, K Erkmen, R J Parker, R Stevens and J M Collins
      Drug Metabolism and Disposition March 1994, 22 (2) 254-258;

  5. Suttle, A B

    1. Bile flow but not enterohepatic recirculation influences the pharmacokinetics of ranitidine in the rat.
      A B Suttle and K L Brouwer
      Drug Metabolism and Disposition March 1994, 22 (2) 224-232;

  6. Szuna, A

    1. Disposition of [14C]acitretin in humans following oral administration.
      F Rubio, B K Jensen, L Henderson, W A Garland, A Szuna and C Town
      Drug Metabolism and Disposition March 1994, 22 (2) 211-215;

T

  1. Tam, S P

    1. Induction and regulation of CYP2E1 in murine liver after acute and chronic acetone administration.
      P G Forkert, Z M Redza, S Mangos, S S Park and S P Tam
      Drug Metabolism and Disposition March 1994, 22 (2) 248-253;

  2. Thai, G W

    1. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
      Y Kido, A R Khokhar, M Yoshida, G W Thai and Z H Siddik
      Drug Metabolism and Disposition March 1994, 22 (2) 312-317;

  3. Theoharides, A D

    1. In vitro metabolism of L-696,229, an HIV-1 reverse transcriptase inhibitor in rats and humans. Hepatic and extrahepatic metabolism and identification of enzymes involved in the hepatic metabolism.
      T Prueksaritanont, L M Dwyer, S K Balani and A D Theoharides
      Drug Metabolism and Disposition March 1994, 22 (2) 281-288;

  4. Toja, E

    1. Metabolism of isbufylline in humans. Isolation, identification, and synthesis of plasma and urine metabolites.
      O Agostini, G Bonacchi, G Coppini, E Toja, A Triolo, S Manzini, G Pieraccini and G Moneti
      Drug Metabolism and Disposition March 1994, 22 (2) 259-268;

  5. Town, C

    1. Disposition of [14C]acitretin in humans following oral administration.
      F Rubio, B K Jensen, L Henderson, W A Garland, A Szuna and C Town
      Drug Metabolism and Disposition March 1994, 22 (2) 211-215;

  6. Triolo, A

    1. Metabolism of isbufylline in humans. Isolation, identification, and synthesis of plasma and urine metabolites.
      O Agostini, G Bonacchi, G Coppini, E Toja, A Triolo, S Manzini, G Pieraccini and G Moneti
      Drug Metabolism and Disposition March 1994, 22 (2) 259-268;

  7. Trnovec, T

    1. NG-nitro-L-arginine is not involved in enterohepatic cycling in rats.
      V K Piotrovskij, Z Kállay, J Horecký, T Trnovec, G Raberger and K Krejcy
      Drug Metabolism and Disposition March 1994, 22 (2) 338-339;

  8. Tynes, R

    1. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron.
      V Fischer, A E Vickers, F Heitz, S Mahadevan, J P Baldeck, P Minery and R Tynes
      Drug Metabolism and Disposition March 1994, 22 (2) 269-274;

V

  1. Varga, S L

    1. Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2 (1H)-one (L-696,229), an HIV-1 reverse transcriptase inhibitor, by rat liver slices and in humans.
      S K Balani, L R Kauffman, B H Arison, T V Olah, M E Goldman, S L Varga, J A O'Brien, H G Ramjit, C S Rooney and J M Hoffman
      Drug Metabolism and Disposition March 1994, 22 (2) 200-205;

  2. Vickers, A E

    1. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron.
      V Fischer, A E Vickers, F Heitz, S Mahadevan, J P Baldeck, P Minery and R Tynes
      Drug Metabolism and Disposition March 1994, 22 (2) 269-274;

W

  1. Wheeler, S M

    1. Use of rat and human in vitro systems to assess the effectiveness and enzymology of deoxyguanine analogs as prodrugs of an antiviral agent.
      A W Harrell, S M Wheeler, P East, S E Clarke and R J Chenery
      Drug Metabolism and Disposition March 1994, 22 (2) 189-193;

Y

  1. Yabuki, M

    1. Pharmacokinetics of SM-10888 and its metabolites depending on their physicochemical properties.
      M Yabuki, T Mine, K Iba, I Nakatsuka and A Yoshitake
      Drug Metabolism and Disposition March 1994, 22 (2) 294-297;

  2. Yang, H L

    1. Cytochrome P-450-dependent biotransformation of 2-acetylaminofluorene in cell-free preparations of human embryonic hepatic, adrenal, renal, pulmonary, and cardiac tissues.
      M J Namkung, H L Yang and M R Juchau
      Drug Metabolism and Disposition March 1994, 22 (2) 331-337;

  3. Yoshida, M

    1. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
      Y Kido, A R Khokhar, M Yoshida, G W Thai and Z H Siddik
      Drug Metabolism and Disposition March 1994, 22 (2) 312-317;

  4. Yoshida, T

    1. Pharmacokinetic study of p-chloronitrobenzene in rat.
      T Yoshida
      Drug Metabolism and Disposition March 1994, 22 (2) 275-280;

  5. Yoshitake, A

    1. Pharmacokinetics of SM-10888 and its metabolites depending on their physicochemical properties.
      M Yabuki, T Mine, K Iba, I Nakatsuka and A Yoshitake
      Drug Metabolism and Disposition March 1994, 22 (2) 294-297;

Z

  1. Ziemniak, J A

    1. Dispositional characteristics of a tyrosine kinase inhibitor (RG 14620) in rats and rabbits following intravenous administration or dermal application.
      V K Khetarpal, P M Markham and J A Ziemniak
      Drug Metabolism and Disposition March 1994, 22 (2) 216-223;
Back to top

In this issue

Advertisement